Hukyndra ® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab Exclusive partnership between Alvotech and STADA in Europe includes Hukyndra ® and six biosimilar candidates REYKJAVIK, Iceland and BAD VILBEL, Germany, Sept.

REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication from the U.S.

Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financing Debuted as publicly traded company on Nasdaq Stock Exchange in U.S.

Alvotech releases ESG indicators covering both 2020 and 2021 Carbon neutrality for scope 1 and 2 emissions achieved in 2020 and 2021 ESG portal is now available on the Company’s website at www.alvotech.com/corporate-sustainability Alvotech founder Robert Wessman: “We believe that biosimilars are

Alvotech has now entered four biosimilar candidates into confirmatory patient studies Combined sales of Prolia ® and Xgeva ® (denosumab) which are used to treat bone diseases were nearly $5.3 billion in 2021 REYKJAVIK, Iceland, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global

REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in two upcoming

REYKJAVIK, Iceland, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months and second quarter

After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move to the Nasdaq Main Market in Iceland Listing on the Main Market can increase visibility and may allow Alvotech to be included in both Icelandic and international indexes REYKJAVIK,

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studies REYKJAVIK, Iceland , July 20, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO),

Four new members enhance independence and diversity of Board of Directors Alvotech is dual listed on NASDAQ in the U.S. and NASDAQ First North Growth Market in Iceland under the symbol “ALVO” REYKJAVIK, Iceland, July 14, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company